Products for Research Use Only
RegisterLogin

Lifitegrast

CAT: 0804-HY-19344-01Size: 5 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-19344-01Size:5 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Lifitegrast (SAR 1118) is a potent integrin antagonist. Lifitegrast blocks the binding of intercellular adhesion molecule 1 (ICAM-1) to lymphocyte function-associated antigen 1 (LFA-1), interrupting the T cell-mediated inflammatory cycle. Lifitegrast inhibits Jurkat T cell attachment to ICAM-1 with an IC50 of 2.98 nM. Lifitegrast can be used for researching dry eye disease[1].
CAS Number
1025967-78-5
Product Name Alternative
SAR 1118; SHP-606
UNSPSC
12352005
Hazard Statement
H302, H312, H332
Target
Integrin
Type
Reference compound
Related Pathways
Cytoskeleton
Applications
COVID-19-immunoregulation
Field of Research
Inflammation/Immunology
Assay Protocol
https://www.medchemexpress.com/Lifitegrast.html
Purity
99.29
Solubility
DMSO : ≥ 29 mg/mL
Smiles
O=C(O)[C@H](CC1=CC=CC(S(=O)(C)=O)=C1)NC(C2=C(Cl)C3=C(CN(C(C4=CC=C5C=COC5=C4)=O)CC3)C=C2Cl)=O
Molecular Formula
C29H24Cl2N2O7S
Molecular Weight
615.48
Precautions
H302, H312, H332
References & Citations
[1]Perez VL, et al. Lifitegrast, a Novel Integrin Antagonist for Treatment of Dry Eye Disease. Ocul Surf. 2016 Apr;14 (2) :207-15.|[2]Sun Y, et al. Corneal inflammation is inhibited by the LFA-1 antagonist, lifitegrast (SAR 1118) . J Ocul Pharmacol Ther. 2013 May;29 (4) :395-402.|[3]Rao VR, et al. Delivery of SAR 1118 to the retina via ophthalmic drops and its effectiveness in a rat streptozotocin (STZ) model of diabetic retinopathy (DR) . Invest Ophthalmol Vis Sci. 2010 Oct;51 (10) :5198-204.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Launched
Isoform
αLβ2

Alternative Products

CatalogName
BA4581-10Lifitegrast

Popular Products